You are here: Industry Insights > Market News > Lexicon Pharma goes three for three with sotagliflozin data

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Aildenafil Citrate Tablets

Retatrutide 2381089-83-2

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Lexicon Pharma goes three for three with sotagliflozin data

epvantageJune 13, 2017

Tag: Pharma

Favorites

Three proved to be the charm for Lexicon Pharmaceuticals after it reported its third set of positive phase III data for its novel SGLT1/2 drug sotagliflozin in type 1 diabetes.

The results reported at the American Diabetes Association conference not only keep it and partner Sanofi on track for a first-quarter filing next year, but the continued efficacy and safety data could lend support for the two groups’ further efforts in the crowded type 2 diabetes field.

Previous:Precision medicine data on DS-8201

Next:NemaMetrix introduces Fluorescent Staining Kits

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Lexicon Pharma goes three for three with sotagliflozin data | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

Grape Seed Extract 95% OPC Plant extract Pharmaceutical made in china

Sermorelin Pharmaceutical Polypeptide supplier API made in china

Marya Pharmaceutical Clean Room H13 H14 Panel Type 99.999% HEPA Filter for Dust Free Factory

spray bottle PET plastic spray bottle Pharmaceutical xinjitai PET bottlesYY057-30

ZP35B/ZP37B/ZP39i Rotary Tablet Press-Pharmaceutical Machinery

PPGI/Ss Steel/HPL /PU/Rock Wool/EPS Customized Modular Cleanroom Sandwich Panel for Pharmaceutical

1-(2-Furoyl)piperazine other active pharmaceutical ingredients

Balsalazide CP Pharmaceutical Digestive system drugs made in china

Nafamostat Mesylate other active pharmaceutical ingredients

Bekanamycin B Pharmaceutical Antibiotics Intermediate arbekacin sulfate made in china

Lexicon Pharma goes three for three with sotagliflozin data

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may likeMore>>

You may like
More>>